Share ownership Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 12:00:00 12/06/2026 pm IST			5-day change	1st Jan Change
5,082.00 ^JPY	+0.97%		+3.17%	+5.11%

11/06	Takeda Pharmaceutical's Psoriasis Treatment Beats Competitor in Trial	MT
11/06	Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial	RE

Share class: Takeda Pharmaceutical Company Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	1,59,12,62,509	1,57,93,38,567 ( 99.25 %)	1,13,92,279 ( 0.7159 %)	99.25 %

Major shareholders: Takeda Pharmaceutical Company Limited

Name	Stocks	%	Valuation
BlackRock Fund Advisors 3.733 %	5,94,01,184	3.733 %	1 910 M ¥
BlackRock Japan Co. Ltd. 2.263 %	3,60,14,900	2.263 %	1 158 M ¥
Amova Asset Management Co., Ltd. 2.151 %	3,42,32,400	2.151 %	1 101 M ¥
Nippon Life Insurance Co. 1.555 %	2,47,52,000	1.555 %	796 M ¥
BlackRock Advisors (UK) Ltd. 0.7854 %	1,24,98,388	0.7854 %	402 M ¥
BlackRock Investment Management (UK) Ltd. 0.4565 %	72,63,768	0.4565 %	234 M ¥
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.3952 %	62,88,500	0.3952 %	202 M ¥
BlackRock (Netherlands) BV 0.3613 %	57,48,780	0.3613 %	185 M ¥
Lazard Japan Asset Management KK 0.1935 %	30,79,600	0.1935 %	99 M ¥
Takeda Pharmaceutical Employee Incentive Plan 0.186 %	29,59,895	0.186 %	95 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Capital Research & Management Co. (Global Investors) 0.6003 %	1,91,04,219	0.6003 %	305 M ¥
Fidelity Management & Research Co. LLC 0.2236 %	71,17,486	0.2236 %	114 M ¥
Eaton Vance Management 0.2033 %	64,69,600	0.2033 %	103 M ¥
Adage Capital Partners GP LLC 0.2019 %	64,24,984	0.2019 %	103 M ¥
Goldman Sachs Wealth Services LP 0.1765 %	56,18,728	0.1765 %	90 M ¥
Brandes Investment Partners LP 0.1392 %	44,30,642	0.1392 %	71 M ¥
BlackRock Institutional Trust Co. NA 0.0998 %	31,74,585	0.0998 %	51 M ¥
Arrowstreet Capital LP 0.0979 %	31,16,311	0.0979 %	50 M ¥
Renaissance Technologies LLC 0.0939 %	29,89,100	0.0939 %	48 M ¥
UBS Financial Services, Inc. 0.0861 %	27,40,229	0.0861 %	44 M ¥
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	19.96%
Others	1.64%
Takeda Pharmaceutical Co., Ltd.	0.4%
Individuals	0.2%
Iyogin Holdings, Inc.	0.18%
Medipal Holdings Corp.	0.03%
SEI Investments Co.	0.01%
The Shiga Bank, Ltd.	0.01%
Unknown	77.57%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	10.54%
Japan	7.42%
United Kingdom	2.28%
Netherlands	0.51%
Canada	0.23%
Sweden	0.22%
Hong Kong	0.21%
Individuals	0.2%
Taiwan	0.17%
Australia	0.12%
Ireland	0.12%
Luxembourg	0.09%
Denmark	0.08%
Singapore	0.05%
Finland	0.04%
Germany	0.04%
Belgium	0.02%
France	0.02%
Switzerland	0.02%
Mexico	0.01%
Norway	0.01%
Spain	0.01%
New Zealand	0.01%
Austria	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Employees

47,455

Sector

Pharmaceuticals

Calendar

Earnings release - Q1 2027

More about the company